Device Trial Radar · NCT06272084
Analysis of TPE Treatments With multiFiltratePRO
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
May 22, 2024
Primary completion
Feb 22, 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Fresenius Medical Care Deutschland GmbHNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- X-act Cologne Clinical Research GmbH
- First posted
- Feb 22, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Analysis of therapeutic plasma exchange (TPE) treatments to assess the performance of the TPE mode of multiFiltratePRO based on the successful exchange of plasma from whole blood. The multiFiltratePRO is a device for extracorporeal blood purification treatments.
Conditions
- Autoimmune Diseases
Interventions
Therapeutic Plasma Exchange (TPE) option of multiFiltratePRODevice
Retrospective Data Analysis of TPE treatments with multiFiltratePRO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total amount of exchange plasma (prescribed vs achieved exchange volume)Time frame: through study completion, an average of 1 year
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Klinikum Aschaffenburg-Alzenau
Aschaffenburg, Bavaria, Germany
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.